CoChat
Sign Up
Cited by 22Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and ApplicationsNuclear Physics and Applications

The DOI matches its Crossref record; 219 of the 278 references it cites were found in a registry or an index.

Production and Clinical Applications of Radiopharmaceuticals and Medical Radioisotopes in Iran

Jalilian, Amir Reza, Beiki, Davood, Hassanzadeh-Rad, Arman, Eftekhari, Arash, Geramifar, Parham, Eftekhari, Mohammad·2016·Seminars in Nuclear Medicine
DOI 10.1053/j.semnuclmed.2016.01.006
Open this paper in CoChat — free account

Abstract

During past 3 decades, nuclear medicine has flourished as vibrant and independent medical specialty in Iran. Since that time, more than 200 nuclear physicians have been trained and now practicing in nearly 158 centers throughout the country. In the same period, Tc-99m generators and variety of cold kits for conventional nuclear medicine were locally produced for the first time. Local production has continued to mature in robust manner while fulfilling international standards. To meet the ever-growing demand at the national level and with international achievements in mind, work for production of other Tc-99m-based peptides such as ubiquicidin, bombesin, octreotide, and more recently a kit formulation for Tc-99m TRODAT-1 for clinical use was introduced. Other than the Tehran Research Reactor, the oldest facility active in production of medical radioisotopes, there is one commercial and three hospital-based cyclotrons currently operational in the country. I-131 has been one of the oldest radioisotope produced in Iran and traditionally used for treatment of thyrotoxicosis and differentiated thyroid carcinoma. Since 2009, (131)I-meta-iodobenzylguanidine has been locally available for diagnostic applications. Gallium-67 citrate, thallium-201 thallous chloride, and Indium-111 in the form of DTPA and Oxine are among the early cyclotron-produced tracers available in Iran for about 2 decades. Rb-81/Kr-81m generator has been available for pulmonary ventilation studies since 1996. Experimental production of PET radiopharmaceuticals began in 1998. This work has culminated with development and optimization of the high-scale production line of (18)F-FDG shortly after installation of PET/CT scanner in 2012. In the field of therapy, other than the use of old timers such as I-131 and different forms of P-32, there has been quite a significant advancement in production and application of therapeutic radiopharmaceuticals in recent years. Application of (131)I-meta-iodobenzylguanidine for treatment of neuroblastoma, pheochromocytoma, and other neuroendocrine tumors has been steadily increasing in major academic university hospitals. Also (153)Sm-EDTMP, (177)Lu-EDTMP, (90)Y-citrate, (90)Y-hydroxyapatite colloid, (188/186)Re-sulfur colloid, and (188/186)Re-HEDP have been locally developed and now routinely available for bone pain palliation and radiosynovectomy. Cu-64 has been available to the nuclear medicine community for some time. With recent reports in diagnostic and therapeutic applications of this agent especially in the field of oncology, we anticipate an expansion in production and availability. The initiation of the production line for gallium-68 generator is one of the latest exciting developments. We are proud that Iran would be joining the club of few nations with production lines for this type of generator. There are also quite a number of SPECT and PET tracers at research and preclinical stage of development preliminarily introduced for possible future clinical applications. Availability of fluorine-18 tracers and gallium-68 generators would no doubt allow rapid dissemination of PET/CT practices in various parts of our large country even far from a cyclotron facility. Also, local production and availability of therapeutic radiopharmaceuticals are going to open exciting horizons in the field of nuclear medicine therapy. Given the available manpower, local infrastructure of SPECT imaging, and rapidly growing population, the production of Tc-99m generators and cold kit would continue to flourish in Iran.

Overview

Integrity signals

Registry

Crossref · 10.1053/j.semnuclmed.2016.01.006

Cites

219 of 219 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Research works printed but not linked: 47

  1. Yaraghchi, 1995, Synthesis, formulation and quality control of Mebrofenin (BRIDA) as a 99mTc-KIT for cholescintigraphy, Iran J Nucl Med, 3, 21
  2. Eftekhari, 1993, Measurement of glomerular filtration rate with Tc-99m DTPA, Iran J Nucl Med, 1, 30
  3. Alavi, 2002, Comparative assessment of renal Tc-99m DMSA scan and renal sonography findings in complication of urinary tract infections, Iran J Nucl Med, 10, 7
  4. Eftekhari, 1998, Evaluation of ocular hydroxyapatite implant with Tc-99m MDP bone scan, Iran J Nucl Med, 6, 1
  5. Eftekhari, 1997, Role of Tc-99m MIBI scintigraphy in diagnosis of malignant breast tumors, Iran J Nucl Med, 5, 1
  6. Saghari, 1995, Imaging of medullary thyroid carcinoma with Tc-99m (V) DMSA, Iran J Nucl Med, 3, 4
  7. Eftekhari, 1994, Tc-99m-RBC scan in diagnosis of hepatic hemangioma, Iran J Nucl Med, 2, 50
  8. Yaraghchi, 1994, Preparation of human serum albumin microspheres (MSA) kit for lung imaging in Iran, Iran J NuclMed, 2, 29
  9. Doroudi, 2015, Clinical evaluation of 99mTc-MDP three phase bone scan and 99mTc-UBI [29-41] scintigraphy imaging in preferentially detection infection from sterile inflammation among diabetic patients with suspected foot infection, IOSR J Pharm, 5, 20
  10. Erfani, 2013, Preparation and biological evaluation of [99mTc/EDDA/Tricine/HYNIC0, BzThi3]-octreotide for somatostatin receptor-positive tumor imaging, Cancer Biother Radiopharm, 28, 240
  11. Fateh, 1995, The radioisotope 67Ga (T1/2 = 78h) in extensively used as single photon marker for detecting the presence, Iran J Nucl Med, 3, 41
  12. Hadizad, 1993, Radiolabelling of white blood cells with In-111 and Tc-99m, Iran J Nucl Med, 1, 34
  13. Aboudzadeh Rovais, 2010, Design and manufacture of krypton gas target for 81Rb production at a 30MeV cyclotron, Nukleonika, 55, 225
  14. Akhlaghi, 2006, Production and quality control of sodium fluoride (Na18F) and it’s distribution in rat’s lesions as PET radiopharmaceutical for bone scan, Iran J Nucl Sci Technol, 36, 24
  15. Jalilian, 1999, Production and quality control of [18F]-FDG in Iran, Iran J Nucl Med, 7, 14
  16. Beiki, 2013, Effectiveness and complications of 153Sm-EDTMP in palliative treatment of diffuse skeletal metastases, Iran J Nucl Med, 21, 26
  17. Bahrami-Samania, 2012, Production, quality control and pharmacokinetic studies of177Lu-EDTMP for human bone pain palliation therapy trialsservices, Iran J Pharm Res, 11, 137
  18. Norouzbeigi, 2015, Efficacy of radiosynovectomy in the treatment of chronic knee synovitis: Systematic review and meta-analysis, Iran J Nucl Med, 23, 59
  19. Mortazavi, 2007, (32)P colloid radiosynovectomy in treatment of chronic haemophilicsynovitis: Iran experience, Haemophilia, 13, 182
  20. Beiki, 2015, Effectiveness and complications of 188Re-HEDP in palliative treatment of diffuse skeletal metastases, Iran J Nucl Med, 23, 44
  21. Targholizadeh, 2010, Cyclotron production of technetium radionuclides using natural metallic molybdenum target and consequent preparation of 99mTc-BRIDA as a sample radiopharmaceutical, Nukleonika, 55, 113
  22. Fakhari, 2016, Development of In-111-DTPA-bis-alendronate complexes for bone pain palliation therapy, Front Biomed Technol, 2, 163
  23. Sadeghi, 2014, Development of 111In-labeled porphyrins for SPECT imaging, Asia Ocean J Nucl Med Biol, 2, 95
  24. Fazaeli, 2012, Radiosynthesis and biological evaluation of [111In]-5, 10, 15, 20-tetrakis (pentafluorophenyl) porphyrin complex as a possible imaging agent, Int J Nucl Energy Sci Eng, 2, 28
  25. Jalilian, 2005, Preparation of [111In]Bleomycin, Iran J Nucl Med, 23, 19
  26. Jalilian, 2010, Biological evaluation of [67Ga]-DTPA-glucagon for SPECT imaging, J Radioanal NuclChem, 285, 555
  27. Tabeie, 2003, Dynamic distribution of 67Ga-Bleomycin complex in normal mice, Iran J Pharmacol Ther, 1, 24
  28. Jalilian, 2006, Preparation and quality Control of [57Co]Bleomycins, Iran J Nucl Sci Technol, 38, 4
  29. Aghanejad, 2016, Optimized production and quality control of 68Ga-DOTATATE, Iran J Nucl Med, 24, 29
  30. Aghanejad, 2015, Production and quality control of [68Ga]Citrate for PET applications, Asia Ocean J Nucl Med Biol, 3, 99
  31. Fazaeli, 2010, Production, quality control and imaging of 64Cu-ATSM in healthy rabbits for PET applications, Iran J Nucl Med, 18, 14
  32. Akhlaghi, 2009, Radiosynthesis and biological evaluation of [18F]-tetracosactide using a semi-automated 18F-SFB production module, J Nucl Sci Tech, 20, 163
  33. Jalilian, 2008, 61Cu-PTSM in normal rats, J Nucl Sci Technol, 19, 159
  34. Jalilian, 2009, Preparation, quality control and biodistribution studies of [61Cu]-doxorubicin for PET tumor imaging, J Nucl Sci Tech, 20, 157
  35. Jalilian, 2008, Preparation and preclinical evaluation of [61Cu]-thiophene-2-aldehyde thiosemicarbazone for PET studies, Nucl Med Rev, 11, 41
  36. Jalilian, 2009, Preparation and biological evaluation of [61Cu]Bleomycin complex as a possible PET radiopharmaceutical, Nukleonika, 54, 135
  37. Rowshanfarzad, 2004, Simultaneus production and quality control of 73Se and 75Se radioisotopes in a 30MeV cyclotron, Iran J Radiat Res, 2, 45
  38. Adeli, 2010, Production, quality control and biological evaluation of 90Y-EDTMP in rats, J Nucl Sci Technol, 52, 40
  39. Vahidfar, 2014, Radiosynthesis and biological evaluation of holmium-166 labeled methoxylatedporphyrins as possible therapeutic agents, J Radioanal Nucl Chem, 301, 269
  40. Naseri, 2011, Preparation and Bio-kinetics of samarium-153 maltolate complex as a lanthanide mobilization product in rats, Sci Pharm, 79, 265
  41. Yousefnia, 2014, Development of 177Lu-phytate complex for radiosynovectomy, World J Nucl Med, 3, 22
  42. Zolghadri, 2014, Development of 166Ho-PDTMP as a possible bone palliation agent, World J Nucl Med, 13, 28
  43. Gholipour, 2013, Optimization of 90Y-antiCD20 preparation for radioimmunotherapy, J Cancer Res Therapeut, 9, 199
  44. Shirvani-Arani, 2011, Preparation, quality control and biodistribution studies of 165Dy-chitosan for radiosynovectomy, Nukleonika, 56, 277
  45. Bahrami-Samani, 2009, Development of 153Sm-DTPA-Rituximab for radioimmunotherapy, Nukleonika, 54, 271
  46. Sadeghi, 2007, Dosimetry of (32)Pradiocolloid for treatment of cystic craniopharyngioma, Appl Radiat Isot, 65, 519
  47. Jalilian, 2004, Preparation, biodistribution and stability of [65Zn]bleomycin complex, Daru, 12, 115

Cited by

Sorted by citations

See all 22

Related

See all

Metadata

Authors
Jalilian, A. R., Beiki, D., Hassanzadeh-Rad, A., Eftekhari, A., Geramifar, P., & Eftekhari, M.
Affiliations
  • Nuclear Science and Technology Research Institute (IR)
  • Shariati Hospital (IR)
  • Surrey Memorial Hospital (CA)
Corresponding author
Eftekhari, Mohammad
ORCID
Venue
Seminars in Nuclear Medicine
Publisher
Elsevier BV
Published
2016-07
Volume
46
Issue
4
Pages
340-358
ISSN
0001-2998 (ISSN-L)
DOI
10.1053/j.semnuclmed.2016.01.006
OpenAlex
W2403746937
Cited by
22
References
278
Citations by year
2026: 1 · 2025: 3 · 2024: 2 · 2023: 1 · 2022: 3 · 2020: 3 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 3
FWCI
0.46
Type
journal article
Language
en
Update notices
erratum (2016-11-01)
Open access
closed
Licence
Locations
  • Seminars in Nuclear Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Physical Sciences › Physics and Astronomy › Radiation › Nuclear Physics and Applications
Keywords
radiopharmaceuticals, medical radioisotopes, Iran, iodine-131, gallium-67 citrate, thallium-201, indium-111, 18F-FDG, PET/CT, therapeutic radiopharmaceuticals, radionuclide therapy
MeSH terms
Humans, Iran, Radioisotopes, Radiopharmaceuticals

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review